Tarsus Pharmaceuticals, Inc. — Director's Dealing 2021

Jun 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2021-06-23

Reporting Person: Vivo Capital IX, LLC (10% Owner)
Reporting Person: Vivo Capital Fund IX, L.P. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-23	Common Stock	S	37980	$29.8	Disposed	3005035	Indirect
2021-06-24	Common Stock	S	10000	$29.9	Disposed	2995035	Indirect
2021-06-25	Common Stock	S	7704	$29.6	Disposed	2987331	Indirect

Footnotes

F1: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.6 to $28.3, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.2 to $29.7, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.0 to $29.5, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4: The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.